Polysaccharide-Based Biomaterials for Protein Delivery

Leader, 2008, Protein therapeutics: a summary and pharmacological classification, Nat Rev Drug Discov, 7, 21, 10.1038/nrd2399 Walsh, 2018, Biopharmaceutical benchmarks 2018, Nat Biotechnol, 36, 1136, 10.1038/nbt.4305 Kintzing, 2016, Emerging strategies for developing next-generation protein therapeutics for cancer treatment, Trends Pharmacol Sci, 37, 993, 10.1016/j.tips.2016.10.005 Vaishya, 2015, Long-term delivery of protein therapeutics, Expert Opin Drug Deliv, 12, 415, 10.1517/17425247.2015.961420 Shi, 2017, Cancer nanomedicine: progress, challenges and opportunities, Nat Rev Cancer, 17, 20, 10.1038/nrc.2016.108 Blanco, 2015, Principles of nanoparticle design for overcoming biological barriers to drug delivery, Nat Biotechnol, 33, 941, 10.1038/nbt.3330 Gu, 2011, Tailoring nanocarriers for intracellular protein delivery, Chem Soc Rev, 40, 3638, 10.1039/c0cs00227e Mo, 2014, Emerging micro-and nanotechnology based synthetic approaches for insulin delivery, Chem Soc Rev, 43, 3595, 10.1039/c3cs60436e Vermonden, 2012, Hydrogels for protein delivery, Chem Rev, 112, 2853, 10.1021/cr200157d Solaro, 2010, Targeted delivery of protein drugs by nanocarriers, Materials, 3, 1928, 10.3390/ma3031928 Lu, 2014, Stimuli-responsive nanomaterials for therapeutic protein delivery, J Control Release, 194, 1, 10.1016/j.jconrel.2014.08.015 Zhu, 2019, Dynamic covalent chemistry-regulatedstimuli-activatable drug delivery systems for improved cancer therapy, Chin Chem Lett Li, 2019, Redox dual-stimuli responsive drug delivery systems for improving tumor-targeting ability and reducing adverse side effects, Asian J Pharm Sci Liu, 2008, Polysaccharides-based nanoparticles as drug delivery systems, Adv Drug Deliv Rev, 60, 1650, 10.1016/j.addr.2008.09.001 Alvarez-Lorenzo, 2013, Crosslinked ionic polysaccharides for stimuli-sensitive drug delivery, Adv Drug Deliv Rev, 65, 1148, 10.1016/j.addr.2013.04.016 Toole, 2004, Hyaluronan: from extracellular glue to pericellular cue, Nat Rev Cancer, 4, 528, 10.1038/nrc1391 Kim, 2017, Hyaluronate and its derivatives for customized biomedical applications, Biomaterials, 123, 155, 10.1016/j.biomaterials.2017.01.029 Götte, 2006, Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective, Cancer Res, 66, 10233, 10.1158/0008-5472.CAN-06-1464 Guo, 2017, Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner, Oncogene, 36, 2457, 10.1038/onc.2016.404 Hou, 2012, The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers, Cell Res, 22, 259, 10.1038/cr.2011.139 Aruffo, 1990, CD44 is the principal cell surface receptor for hyaluronate, Cell, 61, 1303, 10.1016/0092-8674(90)90694-A Zöller, 2011, CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?, Nat Rev Cancer, 11, 254, 10.1038/nrc3023 Rodrigues, 2019, Circulating tumor cells: come together, right now, over metastasis, Cancer Discov, 9, 22, 10.1158/2159-8290.CD-18-1285 Zheng, 2018, Self-assembled dual fluorescence nanoparticles for CD44-targeted delivery of anti-miR-27a in liver cancer theranostics, Theranostics, 8, 3808, 10.7150/thno.25255 Lv, 2018, Nanoplatform assembled from a CD44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and cancer cells, ACS Nano, 12, 1519, 10.1021/acsnano.7b08051 Benitez, 2011, Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells, Cancer Res, 71, 4085, 10.1158/0008-5472.CAN-10-4610 Lokeshwar, 2008, Hyalurondiase: both a tumor promoter and suppressor, Semin Cancer Biol, 18, 281, 10.1016/j.semcancer.2008.03.008 Stern, 2008, Hyaluronidases in cancer biology, Semin Cancer Biol, 18, 275, 10.1016/j.semcancer.2008.03.017 Choi, 2011, Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy, ACS Nano, 5, 8591, 10.1021/nn202070n Sun, 2019, Hyaluronic acid-targeted and pH-responsive drug delivery system based on metal-organic frameworks for efficient antitumor therapy, Biomaterials, 223, 119473, 10.1016/j.biomaterials.2019.119473 Varghese, 2009, In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach, J Am Chem Soc, 131, 8781, 10.1021/ja902857b Jiang, 2014, Gel-liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy, Adv Funct Mater, 24, 2295, 10.1002/adfm.201303222 Zhou, 2019, Co-delivery of TRAIL and siHSP70 using hierarchically modular assembly formulations achieves enhanced TRAIL-resistant cancer therapy, J Control Release, 304, 111, 10.1016/j.jconrel.2019.05.013 Liu, 2018, Hierarchical nanoassemblies-assisted combinational delivery of cytotoxic protein and antibiotic for cancer treatment, Nano Lett, 18, 2294, 10.1021/acs.nanolett.7b04976 Zhu, 2018, Tumor-specificself-degradable nanogels as potential carriers for systemic delivery of anticancer proteins, Adv Funct Mater, 28, 1707371, 10.1002/adfm.201707371 Yu, 2018, Glucose-responsive oral insulin delivery for postprandial glycemic regulation, Nano Res, 12, 1539, 10.1007/s12274-018-2264-9 Byeon, 2014, Four-armPEGcross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer, Acta Biomater, 10, 142, 10.1016/j.actbio.2013.08.046 Xu, 2013, Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-alpha2a for liver cancer therapy, J Control Release, 166, 203, 10.1016/j.jconrel.2013.01.008 Yu, 2015, Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery, Proc Natl Acad Sci U S A, 112, 8260, 10.1073/pnas.1505405112 Wang, 2016, Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody, Nano Lett, 16, 2334, 10.1021/acs.nanolett.5b05030 Arasukumar, 2019, Chemical composition, structural features, surface morphology and bioactivities of chitosan derivatives from lobster thenus unimaculatus shells, Int J Biol Macromol, 135, 1237, 10.1016/j.ijbiomac.2019.06.033 Aiba, 1992, Studies on chitosan: 4. Lysozymic hydrolysis of partially N-acetylated chitosans, Int J Biol Macromol, 14, 225, 10.1016/S0141-8130(05)80032-7 Hosseinnejad, 2016, Evaluation of different factors affecting antimicrobial properties of chitosan, Int J Biol Macromol, 85, 467, 10.1016/j.ijbiomac.2016.01.022 Perinelli, 2018, Chitosan-based nanosystems and their exploited antimicrobial activity, Eur J Pharm Sci, 117, 8, 10.1016/j.ejps.2018.01.046 Jayakumar, 2011, Biomaterials based on chitin and chitosan in wound dressing applications, Biotechnol Adv, 29, 322, 10.1016/j.biotechadv.2011.01.005 Khan, 2019, A review on recent advances in chitosan based composite for hemostatic dressings, Int J Biol Macromol, 124, 138, 10.1016/j.ijbiomac.2018.11.045 Matica, 2019, Chitosan as a wound dressing starting material: Antimicrobial properties and mode of action, Int J Mol Sci, 20, 5889, 10.3390/ijms20235889 Dyondi, 2013, A nanoparticulate injectable hydrogel as a tissue engineering scaffold for multiple growth factor delivery for bone regeneration, Int J Nanomedicine, 8, 47 Chiu, 2011, Controlled release of thymosin β4 using collagen–chitosan composite hydrogels promotes epicardial cell migration and angiogenesis, J Control Release, 155, 376, 10.1016/j.jconrel.2011.05.026 Xiao, 2016, Diabetic wound regeneration using peptide-modified hydrogels to target re-epithelialization, Proc Natl Acad Sci U S A, 113, E5792, 10.1073/pnas.1612277113 Sonaje, 2009, In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery, Biomaterials, 30, 2329, 10.1016/j.biomaterials.2008.12.066 Liu, 2019, Enhancement of oral bioavailability of salmon calcitonin through chitosan-modified, dual drug-loaded nanoparticles, Int J Pharm, 557, 170, 10.1016/j.ijpharm.2018.12.053 Lee, 2000, Regional oral absorption, hepatic first-pass effect, and non-linear disposition of salmon calcitonin in beagle dogs, Eur J Pharm Biopharm, 50, 205, 10.1016/S0939-6411(00)00102-8 Kumar, 2016, Why chitosan? From properties to perspective of mucosal drug delivery, Int J Biol Macromol, 91, 615, 10.1016/j.ijbiomac.2016.05.054 Mi, 2008, Oral delivery of peptide drugs using nanoparticles self-assembled by poly (γ-glutamic acid) and a chitosan derivative functionalized by trimethylation, Bioconjug Chem, 19, 1248, 10.1021/bc800076n Omid, 2018, In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery, Int J Pharm, 535, 293, 10.1016/j.ijpharm.2017.11.020 Shrestha, 2016, Thiolation and cell-penetrating peptide surface functionalization of porous silicon nanoparticles for oral delivery of insulin, Adv Funct Mater, 26, 3405, 10.1002/adfm.201505252 dos Santos, 2015, Polysaccharide nanoparticles for protein and peptide delivery: exploring less-known materials, Adv Protein Chem Struct Biol, 98, 223, 10.1016/bs.apcsb.2014.11.003 Hudson, 2014, Biopolymer nanoparticle production for controlled release of biopharmaceuticals, Crit Rev Biotechnol, 34, 161, 10.3109/07388551.2012.743503 Minimol, 2013, PEGylated starch acetate nanoparticles and its potential use for oral insulin delivery, Carbohydr Polym, 95, 1, 10.1016/j.carbpol.2013.02.021 Liu, 2018, pH- and amylase-responsive carboxymethyl starch/poly(2-isobutyl-acrylic acid) hybrid microgels as effective enteric carriers for oral insulin delivery, Biomacromolecules, 19, 2123, 10.1021/acs.biomac.8b00215 Ling, 2013, Dissolving polymer microneedle patches for rapid and efficient transdermal delivery of insulin to diabetic rats, Acta Biomater, 9, 8952, 10.1016/j.actbio.2013.06.029 Tiwari, 2019, Derivatization approaches and applications of pullulan, Adv Colloid Interface Sci, 269, 296, 10.1016/j.cis.2019.04.014 Nochi, 2010, Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines, Nat Mater, 9, 572, 10.1038/nmat2784 Muraoka, 2014, Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity, ACS Nano, 8, 9209, 10.1021/nn502975r Kawasaki, 2016, Magnetically guided protein transduction by hybrid nanogel chaperones with iron oxide nanoparticles, Angew Chem Int Ed, 55, 11377, 10.1002/anie.201602577 Uenaka, 2007, T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein, Cancer Immun, 7, 9 Kageyama, 2008, Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel, Cancer Sci, 99, 601, 10.1111/j.1349-7006.2007.00705.x Huang, 2019, Preparation and drug delivery of dextran-drug complex, Drug Deliv, 26, 252, 10.1080/10717544.2019.1580322 Zinderman, 2006, Anaphylactoid reactions to dextran 40 and 70: reports to the United States food and drug administration, 1969 to 2004, J Vasc Surg, 43, 1004, 10.1016/j.jvs.2006.01.006 Fishbane, 2000, The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate, Semin Dial, 13, 381, 10.1046/j.1525-139x.2000.00104.x Bachelder, 2008, Acetal-derivatized dextran: an acid-responsive biodegradable material for therapeutic applications, J Am Chem Soc, 130, 10494, 10.1021/ja803947s Broaders, 2011, A biocompatible oxidation-triggered carrier polymer with potential in therapeutics, J Am Chem Soc, 133, 756, 10.1021/ja110468v Dacoba, 2019, Polysaccharide nanoparticles can efficiently modulate the immune response against an HIV peptide antigen, ACS Nano, 13, 4947, 10.1021/acsnano.8b07662 Gu, 2013, Injectable nano-network for glucose-mediated insulin delivery, ACS Nano, 7, 4194, 10.1021/nn400630x Hu, 2017, Relay drug delivery for amplifying targeting signal and enhancing anticancer efficacy, Adv Mater, 29, 1605803, 10.1002/adma.201605803 Chalasani, 2007, A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin, J Control Release, 117, 421, 10.1016/j.jconrel.2006.12.003 Hemker, 2016, A century of heparin, past present and future, J Thromb Haemost, 14, 2329, 10.1111/jth.13555 Casu, 1985, Structure and biological activity of heparin, Adv Carbohydr Chem Biochem, 43, 51, 10.1016/S0065-2318(08)60067-0 Ingle, 2014, A world of low molecular weight heparins (LMWHs) enoxaparin as a promising moiety-a review, Carbohydr Polym, 106, 148, 10.1016/j.carbpol.2014.01.100 O'Brien, 2014, Multicenter dose-finding and efficacy and safety outcomes in neonates and children treated with dalteparin for acute venous thromboembolism, J Thromb Haemost, 12, 1822, 10.1111/jth.12716 Mulloy, 2016, Pharmacology of heparin and related drugs, Pharmacol Rev, 68, 76, 10.1124/pr.115.011247 Aguilar, 1999, Clinical uses of low-molecular-weight heparins, Chest, 115, 1418, 10.1378/chest.115.5.1418 Cohen, 1997, A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease, N Engl J Med, 337, 447, 10.1056/NEJM199708143370702 van der Wall, 2017, Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice, J Thromb Haemost, 15, 74, 10.1111/jth.13563 Prandoni, 2002, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis, Blood, 100, 3484, 10.1182/blood-2002-01-0108 Zhang, 2017, Thrombin-responsive transcutaneous patch for auto-anticoagulant regulation, Adv Mater, 29, 1604043, 10.1002/adma.201604043 Paluck, 2016, Heparin-mimicking polymers: synthesis and biological applications, Biomacromolecules, 17, 3417, 10.1021/acs.biomac.6b01147 Peysselon, 2014, Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis, Matrix Biol, 35, 73, 10.1016/j.matbio.2013.11.001 Tsurkan, 2013, Growth factor delivery from hydrogel particle aggregates to promote tubular regeneration after acute kidney injury, J Control Release, 167, 248, 10.1016/j.jconrel.2013.01.030 Carter, 1982, The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits, Blood, 59, 1239, 10.1182/blood.V59.6.1239.1239 Sun, 2019, Characterization, bioactivity and pharmacokinetic study of a novel carbohydrate-peptide polymer: glycol-splitheparin-endostatin2 (GSHP-ES2), Carbohydr Polym, 207, 79, 10.1016/j.carbpol.2018.11.043 Weitz, 1997, Low-molecular-weight heparins, N Engl J Med, 337, 688, 10.1056/NEJM199709043371007 Ishihara, 2015, Biomedical application of low molecular weight heparin/protamine nano/micro particles as cell- and growth factor-carriers and coating matrix, Int J Mol Sci, 16, 11785, 10.3390/ijms160511785 Kinoda, 2018, Protective effect of FGF-2 and low-molecular-weight heparin/protamine nanoparticles on radiation-inducedhealing-impaired wound repair in rats, J Radiat Res, 59, 27, 10.1093/jrr/rrx044 Takikawa, 2015, Improved angiogenesis and healing in crush syndrome by fibroblast growth factor-2-containinglow-molecular-weight heparin (fragmin)/protamine nanoparticles, J Surg Res, 196, 247, 10.1016/j.jss.2015.03.022